The Faculty Association of AIIMS (FAAIIMS) has urged Health Minister J.P. Nadda to reinstate two faculty members of the institution, who were removed for allegedly misbehaving and manhandling a patient in 2015.
Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.
-
-
A team of students from Hebrew University of Jerusalem has developed unique pressure-sensing socks that, when linked to a smart phone app, warn diabetic patients of developing foot ulcers.
-
A team of US researchers has developed a new biodegradable material with built-in vitamin A which has been shown to reduce scarring in blood vessels.
-
Amgen announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's Biologics License Application (BLA) for ABP 501, a biosimilar candidate to Humira® (adalimumab).
-
Immunocore, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, infectious diseases and autoimmune disease, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead programme, IMCgp100, for the treatment of uveal melanoma. The Orphan Drug status qualifies Immunocore for a number of development incentives and will enable Immunocore to receive fast track registration for IMCgp100, its lead ImmTAC (Immune mobilising mTCR Against Cancer) therapeutic.
(adsbygoogle = window.adsbygoogle || []).push({}); -
Merck , known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.
-
Takeda Pharmaceutical Company Limited announced that the Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application (“NDA”) for a conjugate vaccine to prevent infections caused by Haemophilus influenzae type b (Hib) in children aged from 2 months to under 5 years of age. The vaccine was licensed from Novartis (Switzerland)* in May 2009 (Novartis' product name: VAXEM Hib). The vaccine is supplied as a suspension for injection that does not require reconstitution.
The application approval is based on positive Phase 3 clinical results of a multicenter, randomized, double-blind, parallel-group, comparative study in 416 Japanese children, which evaluated the safety and immunogenicity of this vaccine compared to a Hib vaccine licensed in Japan.
Hib frequently inhabits the nasopharynx (nose and throat) of individuals and can spread to other parts of the body, causing life threatening illness such as meningitis, pneumonia, or sepsis, particularly in young children. Hib meningitis can be fatal or result in long term disability, but can be prevented through immunization.
In April 2014 GlaxoSmithKline plc (GSK) announced a transaction with Novartis which closed in March 2015. As result of this transaction, GSK acquired Novartis’ non-influenza global vaccines business including VAXEM Hib®.
-
A Danish citizen has been diagnosed with the Zika virus, making it the first case discovered in Denmark.
-
Adding more support to the importance of dietary interventions in obese patients, a research said fatty liver is independently associated with heart failure in such people.
-
A team of US researchers has found that e-cigarettes are toxic and can directly attack lung cells, weakening the immune system and boosting bacterial virulence.
RECOMMENDED POSTS
Subscribe with us
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
